Novel tricyclic compounds having a TXA2 antagonizing activity represented by formula (I): <IMAGE> (I) possess a potent antagonizing against thromboxane A2 and also an antiallergic and/or antihistaminic activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.
